Przemysław Kozanecki, President of IASON Sp. z o.o. said, “We are excited that IASON Sp. z.o.o has become a partner in Blue Earth Diagnostics’ European network for the production and distribution of Axumin, which promises to help improve the care of prostate cancer patients in Poland. We look forward to bringing our expertise, capabilities and reliability to support the launch of this new PET imaging agent in Poland.”


About Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics is backed by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC).


About IASON Sp. z o.o.
IASON Sp. z o.o. is the first commercial manufacturer and distributor of radiopharmaceuticals for Positron Emission Tomography (PET) in Poland, used in oncological, cardiological and neurological diagnostics. IASON manufactures and delivers to PET sites on a routine basis 18F- based radio-pharmaceuticals under EU permits both in Poland and abroad. Manufacturing facilities are located in Warsaw, Kielce and Mszczonów and fully meet GMP and national standards. IASON’s employees are one of the most experienced in the sector. IASON is a member of the Synektik Capital Group, listed on the Warsaw Stock Exchange.

Back to HCB News

Molecular Imaging Homepage